We are proud to announce the successful commercialization of the world’s first “dual-vector PCV13 (TT/DT)” through our localization program in Indonesia.
This achievement goes far beyond a product launch — it represents BioKangtai’s first end-to-end technology transfer program to reach market overseas. By enabling local fill-finish production, the vaccine received regulatory approval in Indonesia.
Key highlights:
· Protection against 13 serotypes
· Approved for the full age range: 6 weeks to 5 years
· Supports Indonesia’s national drive for vaccine self-reliance and equitable access
We sincerely thank our Indonesian partner for making this milestone possible. Looking ahead, we will continue to expand technology-transfer partnerships, helping strengthen global health systems and safeguarding communities worldwide.